223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer



Paget disease is commonly asymptomatic and discovered when an imaging test is performed for another clinical indication or when elevated serum alkaline phosphatase is found. Bone pain usually appears late in the disease process and is only present in a minority of patients. For diagnosis, X-ray and bone scan are the most recommended imaging methods; radionuclide imaging of the skeleton has become the standard, since it is the most sensitive test for detecting increased bone activity. For treatment, either bisphosphonates or calcitonin are recommended.


We present a 74-year-old patient diagnosed with prostate cancer in 2001 who developed bone metastases concomitant with a Paget bone disease.


This patient received treatment with Ra-223, having stable disease in bone scan and no relevant toxicities.


There is no clinical experience with Ra-223 and Paget disease, since it is characterized classically as a high bone turnover disease and therefore there is no rationale to administer a drug that has a high bone affinity. Nevertheless, Ra-223 is not contraindicated.

Tumori 2017; 103(Suppl. 1): e53 - e55

Article Type: CASE REPORT



Lina García Cañamaque, Cristina Rioja Parada, Paloma García De la Peña

Article History


Financial support: Funding for writing assistance was provided by Bayer HealthCare.
Conflict of interest: None of the authors has conflict of interest with this submission.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  •  Department of Nuclear Medicine, Centro Integral Oncológico Clara Campal (CIOCC), Hospital de Madrid Sanchinarro, Grupo HM Hospitales, Madrid - Spain
  •  Departament of Rheumatology, Centro Integral Oncológico Clara Campal (CIOCC), Hospital de Madrid Sanchinarro, Grupo HM Hospitales, Madrid - Spain

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.